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Abstract
Background: Intimate partner violence (IPV) including physical, sexual and emotional violence,
causes short and long term ill-health. Brief questions that reliably identify women experiencing IPV
who present in clinical settings are a pre-requisite for an appropriate response from health services
to this substantial public health problem. We estimated the sensitivity and specificity of four
questions (HARK) developed from the Abuse Assessment screen, compared to a 30-item abuse
questionnaire, the Composite Abuse Scale (CAS).
Methods: We administered the four HARK questions and the CAS to women approached by two
researchers in general practice waiting rooms in Newham, east London. Inclusions: women aged
more than 17 years waiting to see a doctor or nurse, who had been in an intimate relationship in
the last year. Exclusions: women who were accompanied by children over four years of age or
another adult, too unwell to complete the questionnaires, unable to understand English or unable
to give informed consent.
Results: Two hundred and thirty two women were recruited. The response rate was 54%. The
prevalence of current intimate partner violence, within the last 12 months, using the CAS cut off
score of ≥3, was 23% (95% C.I. 17% to 28%) with pre-test odds of 0.3 (95% C.I. 0.2 to 0.4). The
receiver operator characteristic curve demonstrated that a HARK cut off score of ≥1 maximises
the true positives whilst minimising the false positives. The sensitivity of the optimal HARK cut-off
score of ≥1 was 81% (95% C.I. 69% to 90%), specificity 95% (95% C.I. 91% to 98%), positive
predictive value 83% (95% C.I. 70% to 91%), negative predictive value 94% (95% C.I. 90% to 97%),
likelihood ratio 16 (95% C.I. 8 to 31) and post-test odds 5.
Conclusion: The four HARK questions accurately identify women experiencing IPV in the past
year and may help women disclose abuse in general practice. The HARK questions could be
incorporated into the electronic medical record in primary care to prompt clinicians to ask about
recent partner violence and to encourage disclosure by patients. Future research should test the
effectiveness of HARK in clinical consultations.
Published: 29 August 2007
BMC Family Practice 2007, 8:49 doi:10.1186/1471-2296-8-49
Received: 8 December 2006
Accepted: 29 August 2007
This article is available from: http://www.biomedcentral.com/1471-2296/8/49
© 2007 Sohal et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Family Practice 2007, 8:49 http://www.biomedcentral.com/1471-2296/8/49
Page 2 of 9
(page number not for citation purposes)
Background
Violence against women is a global issue affecting mil-
lions who experience it and have to live with its conse-
quences [1]. Intimate partner violence (IPV) including
physical, sexual and emotional abuse is a major public
health problem.
The WHO Violence Against Women study [2] found that
the prevalence of lifetime physical violence and sexual
violence by an intimate partner, among ever-partnered
women varied from 15 to 71% in urban and rural settings
in 10 countries. The prevalence of IPV is higher among
women seeking primary care than in community surveys
of the same geographic populations [3].
In a study in 12 east London general practices it was found
that 41% of women waiting to see their general practi-
tioner (GP) or practice nurse had experienced physical
violence from a partner or former partner. 17% had expe-
rienced it within the past year [4].
IPV causes short and long term health problems. From
controlled studies in a wide range of settings, we know
that these include injury, chronic pain, gastrointestinal
and gynaecological conditions (including sexually trans-
mitted diseases) [5]. Consequences of IPV extend to peri-
natal health with it being an independent risk factor for
deficit in gestational weight gain during pregnancy [6]
and strong evidence of an IPV association with low birth
weight [7].
The psychological health problems associated with
domestic violence are no less serious and have psycholog-
ical parallels with the trauma of being taken hostage and
subjected to torture [8]. The most prevalent mental health
sequelae of IPV are depression and post-traumatic stress
disorder [9].
Women who have experienced physical or psychological
violence are fifteen times more likely to abuse alcohol and
nine times more likely to abuse drugs than are non-
abused women, and there is evidence that substance
abuse is a consequence as well as a potential cause of IPV
[10]. Children exposed to domestic violence also often
experience emotional and behavioural problems [11]. In
the developing world it has been shown that children
exposed to severe and recurrent IPV are more likely to be
admitted with severe acute malnutrition [12].
It is difficult to calculate the exact societal economic
impact of IPV but the costs are high. In the United States
annual costs of intimate partner rape, physical assault,
and stalking exceed $5.8 billion, nearly $4.1 billion of
which is for direct medical and mental health care services
[13]. In the United Kingdom the annual cost to the
national health service of physical assaults is £1.2 billion
[14].
The Department of Health in England now recommends
that "All trusts should be working towards routine
enquiry" [15]. In the US, the Family Violence Prevention
fund consensus guidelines recommend that all adolescent
and adult patients should be routinely asked about
domestic violence [16]. Although there is ongoing debate
about the evidence for screening or routine enquiry [17],
there is unquestionably a need for clinicians to ask about
domestic violence more often than they currently do.
A study of women attending general practices in east Lon-
don found that only 17% of women experiencing IPV
reported that their doctor had asked them about domestic
violence [4]. We know that women who are experiencing
violence want to disclose this to trusted doctors and get
support [18], but that a high proportion of women who
are experiencing abuse do not disclose this spontaneously
in clinical consultations [4].
Short questions that reliably identify women experiencing
IPV who present in clinical settings are a pre-requisite for
developing an appropriate response from health services
to this substantial public health problem [19].
Many primary health care professionals, including general
practitioners (GPs) and practice nurses, occasionally
enquire about domestic violence. It has not been ade-
quately determined whether their questions identify
women experiencing IPV.
Short tests
We have identified eleven short tools (see Additional file
1), for identification of women experiencing IPV [20-30].
Only three were validated in primary care settings [20-22].
The first study did not consider sexual abuse and had an
unrepresentative sample: it was able to differentiate
between self identified survivors of abuse and non-abused
patients; there was no evidence that it was able to identify
women who had experienced IPV in a general practice
population [20]. The second reported no sensitivity or
specificity; instead there was correlation between their
tool and the reference test (Abuse Risk Inventory, r = 0.69,
p = 0.01) but this does not necessarily indicate a valid and
specific measure of IPV [21]. The third tool, a single ques-
tion about safety, had low sensitivity, positive and nega-
tive predictive values (9%, 63% & 57% respectively) [22].
Outside of primary care settings, another two instruments
did not consider sexual abuse [23,24]. One reported no
sensitivity or specificity; only those who were positive on
the index test were recruited into the study [23]. The sen-
sitivity, specificity and positive predictive value of theBMC Family Practice 2007, 8:49 http://www.biomedcentral.com/1471-2296/8/49
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other test were too low for use by clinicians (65%, 80% &
51% respectively) [24].
The sixth tool [25] had a low positive predictive value:
56%. The seventh instrument started with an open ques-
tion which makes it difficult to use as a standardised tool
[26] and the eighth, Webster's "self-report check list," was
not validated against an appropriate reference standard so
there was no calculation of test indices [27]. Two further
studies evaluated single item measures [28,29] and con-
cluded that these may not be adequate in assessing for
domestic violence.
We believe that the eleventh instrument, the AAS [30] has
the most potential. Its strengths include that it covers a
wide definition of partner violence which includes sexual
abuse; a number of the aforementioned tools do not
include sexual abuse [20,23,24,28]. It has 5 items rather
than an unsatisfactory single item as is the case with a
number of the tools [22,28,29]. Additionally it has a sim-
ple scoring system which we believe is important in brief
general practice consultations unlike the likert scales used
in 2 of the tools [20,25], the multiple scoring protocols in
one [21] and an open question in another [26]. Finally, it
has also been validated against an appropriate reference
standard, the Index of Spouse Abuse (ISA) [31] unlike
some [27].
However we also feel that the AAS has a number of weak-
nesses. Although the investigators concluded that the AAS
questions were valid, this was based on a correlation
between the score on a three-question version of the AAS
and the ISA. No sensitivity or specificity was reported. Fur-
thermore, the AAS validation was only within the setting
of antenatal care in the US [30]. We do not know whether
this is generalisable to other health care settings and in
other countries, preventing its implementation into UK
clinical practice [32].
More recently, in 2004, the test performance of the AAS
was evaluated against the modified version of the conflict
tactics scale (CTS 2) [33]. The AAS's sensitivity for minor
physical violence was 32% and for severe physical vio-
lence was 61%. It was concluded that it was not sensible
to use the AAS as a screening tool until more evidence was
gathered.
In our study we have adapted the AAS, for use in a general
practice setting, to form the HARK questionnaire (see
table 1). We tested the HARK against the 30-item Com-
posite Abuse Scale (CAS, see table 2) [34].
Methods
We conducted a cross-sectional survey of women in GP
waiting rooms. The fifty-one general practices in New-
ham, a multi-ethnic inner city area of London, were strat-
ified according to the number of doctors and the
proportion of south Asian names on the practice register
[35]. Equal numbers of practices were selected from each
stratification group using a randomisation programme
(SPSS version X). This was in an attempt to ensure that the
practice population reflected the local area population.
Each practice was sent a recruitment letter with informa-
tion about the study. If practices expressed an interest, a
research team member met with the primary care team to
answer any questions. We excluded practices that did not
have a private room available, as then privacy for the sur-
vey could not be provided. If a practice decided not to take
part or was excluded, the reason for this was documented
and another practice was randomly selected from within
the same stratification group.
We approached consecutive women in practice reception
areas waiting to see a doctor or nurse. We included
women aged more than 17 years who in the last year had
been in an intimate relationship. We excluded women
who were accompanied by children over four years of age
or by another adult, were too unwell to complete the
questionnaires, unable to understand English or unable to
give informed consent. In the waiting room, women were
asked to participate in a study designed to improve
women's health care. We sought consent for the adminis-
tration of the HARK and CAS questionnaires in a private
room. All participants were given information on local
domestic violence services. The East London and City eth-
ics committee approved the study.
The number of potentially eligible subjects was recorded
by the researcher in the waiting room. A record was made
of the number of women who were excluded due to the
exclusion criteria, those who the researchers were unable
to approach at very busy times, women who were
approached and agreed that they would be seen by the cli-
Table 1: HARK questions – one point is given for every yes 
answer
H HUMILIATION
Within the last year, have you been humiliated or 
emotionally abused in other ways by your partner or your 
ex-partner?
A AFRAID
Within the last year, have you been afraid of your partner 
or ex-partner?
R RAPE
Within the last year, have you been raped or forced to 
have any kind of sexual activity by your partner or ex-
partner?
K KICK
Within the last year, have you been kicked, hit, slapped or 
otherwise physically hurt by your partner or ex-partner?BMC Family Practice 2007, 8:49 http://www.biomedcentral.com/1471-2296/8/49
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nician first and then undertake the study but were not
seen again ("did not come back"), those who refused par-
ticipation in the waiting room and those who declined
consent in the private room.
The HARK and CAS were self-administered. We expected
to be able to recruit approximately 500 women. On the
assumption that the prevalence of IPV in the past year was
20%, we calculated that there was a 90% chance of esti-
mating sensitivity at 76% or above with this sample size.
The Composite Abuse Scale – the reference standard
The CAS is a relatively robust standard for identifying IPV
in primary care settings. It has an internal reliability
(Cronbach's alpha) of .90 or more for each sub-scale, and
all item-total score correlations of .6 or above [34]. It has
also been validated with a large (1,836) sample of patients
in general practice settings [36]. It is based on a concept of
IPV that includes coercion, not simply violent acts arising
out of conflict. It is recommended as an IPV research
assessment tool by the National Centre for Injury Preven-
tion and Control [37], as it has demonstrated reliability
and validity for measuring the self-reported incidence and
prevalence of IPV. It has evidence of content, construct,
criterion and factorial validity. The CAS measures four
dimensions of abuse inflicted on a woman by her partner:
physical abuse (PA), emotional abuse (EA), severe com-
bined abuse (SCA) and harassment. A preliminary cut-off
score of 3 divides women presenting as abused or non-
abused in general practice settings [36]. The 30 items are
listed in table 2.
HARK – the index test
The acronym HARK denotes four short questions which
represent different components of IPV. "Hark" is an
archaic verb that means "to listen attentively." HARK
arose out of an adaptation of the AAS. In HARK there is a
focus only on IPV (not including that committed by a
stranger), the pregnancy related item has been removed
(so that it can be used in all women), for clarity emotional
and physical violence are separated out into 2 items
(rather than being combined in 1), "humiliation" was
added (as it was thought to be plainer English and have a
wider remit then "emotional abuse"), "rape" was added
(to try to help cue a woman's memory by using language
similar to her own) whilst items relating to fear and phys-
ical violence were directly retained from the AAS. The
HARK questions are listed in table 1.
None of the women who were identified as having suf-
fered abuse requested the researcher to make a direct refer-
ral in order to access specialised services.
Outcomes measures
The rate of current IPV within the last twelve months was
calculated for the CAS (using the cut off score of ≥3) with
95% confidence intervals. This is equal to the prevalence
or pre-test probability of IPV within the last twelve
months.
The rates of IPV within the last twelve months were also
calculated with 95% confidence intervals for the HARK, at
different cut off scores (e.g. HARK cut off score ≥2, means
a HARK score of either 2, 3 or 4). Each woman was iden-
tified as being positive or negative for IPV for each HARK
cut off score and for the CAS cut off score of ≥3. We could
then calculate HARK's sensitivity, specificity, positive pre-
dictive value (PPV – also known as the post-test probabil-
ity), negative predictive value (NPV), likelihood ratios
(LRs) with 95% confidence intervals and post-test odds (=
pre-test odds × LR) at different HARK cut off scores [38].
A receiver operator characteristic (ROC) curve was con-
structed by plotting the sensitivity of each different HARK
Table 2: Dimensions and items of the Composite Abuse Scale
Severe combined 
abuse
Kept me from medical care
Used a knife or gun or other weapon
Locked me in the bedroom
Put foreign objects in my vagina
Refused to let me work outside the home
Raped me
Tried to rape me
Took my wallet and left me stranded
Emotional abuse Told me that I was crazy
Tried to convince family, friends and children 
that I was crazy
Became upset if dinner/housework wasn't done 
when they thought it should be
Told me that I wasn't good enough
Tried to keep me from seeing or talking to my 
family
Told me that I was stupid
Tried to turn my family, friends and children 
against me
Did not let me socialise with my female friends
Told me that I was ugly
Told me no one would ever want me
Blamed me for their violence
Physical abuse Shook me
Hit or tried to hit me with something
Pushed, grabbed or shoved me
Kicked me, bit me or hit with a fist
Slapped me
Threw me
Beat me up
Harassment Harassed me over the telephone
Harassed me at work
Followed me
Hung around outside my houseBMC Family Practice 2007, 8:49 http://www.biomedcentral.com/1471-2296/8/49
Page 5 of 9
(page number not for citation purposes)
cut off against the false positive rate (= 100 - specificity) at
the different HARK cut offs. This was used to determine an
optimal cut off HARK score which maximised the true
positives whilst minimising the false positives.
Multilevel LRs [38] were also calculated at different HARK
scores (e.g. a HARK score of 2 means 2 only, not ≥2, i.e. 2,
3 or 4) with 95% confidence intervals and corresponding
post-test odds. 95% confidence intervals were calculated
in EXCEL. Multilevel LRs allow exploration of the diag-
nostic usefulness of individual HARK scores.
We have used a variety of different methods to assess
HARK's diagnostic accuracy at identifying IPV. Sensitivity
and specificity interpret the HARK results retrospectively
whereas PPVs and NPVs establish the predictive properties
of the HARK in the future. The PPV is the proportion of
women with a specific HARK result who are experiencing
IPV. LRs express a result in terms of the actual chances of
a woman experiencing IPV if her HARK score reaches a
particular level. A LR for a given HARK result gives the
odds that the test result comes from a person who is expe-
riencing IPV. Unlike PPV and NPV, LRs are a good deal
more constant with changes in prevalence. The post test
odds allow background prevalence to be factored into the
LR. Multilevel LRs express HARK's accuracy with level-spe-
cific likelihood ratios. They can be calculated at different
HARK scores (e.g. 1) as opposed to cut offs (e.g. ≥1). They
ensure that the maximum information is derived from the
total range of possible HARK results (0 to 4).
Results
We approached 24 practices and 12 agreed to participate;
11 declined and one was excluded as it had no private
room. Two hundred and thirty two women were recruited
from May to October 2003. Figure 1 shows recruitment of
individual participants to the study. Seven hundred and
thirty seven women did not meet the inclusion criteria.
Fourteen women were not approached because there were
too many women in the waiting room for all to be
approached. Two hundred and three women "did not
come back." One hundred and eighty six women declined
participation in the waiting room. Eleven women
declined consent in the private room. The response rate of
54% (232/(232 + 186 + 11) was adjusted for the women
who "did not come back."
The average age of participants was 35 years (range 18–70
years). 51% were in a paid job and 53% owned a house or
flat. 40% of participants described their ethnic origin as
white British, 25% as black British, African or Caribbean
and 18% as Indian, Pakistani or Bangladeshi.
Outcomes measures
The CAS identified 53 cases of current IPV in the study
population. This produced a prevalence (pre-test proba-
bility) of current IPV of 23% (95% C.I. 17% to 28%) with
pre-test odds of 0.30 (95% C.I. 0.23 to 0.38). Pretest odds
are prevalence divided by one minus prevalence.
Table 3 gives the sensitivity, specificity, PPV, NPV, LRs and
post-test odds of HARK at different cut off scores. The
receiver operator characteristic curve (figure 2) demon-
strated that a HARK score ≥1 is the optimal cut off for
detecting IPV. The predictive properties of the HARK score
of ≥1 are highlighted in table 3. The HARK test accuracy
(using a cut-off of ≥1) is 92%. This represents the propor-
tion of true positives and true negatives as a proportion of
all results.
Table 3: The sensitivity, specificity, PPV, NPV, LR & post-test odds with 95% confidence intervals of HARK at different cut off scores
Hark cut off 
scores
% of study 
sample
Sensitivity 
with 95% C.I.
Specificity 
with 95% C.I.
Positive 
predictive 
value with 
95% C.I.
Negative 
predictive 
value with 
95% C.I.
Likelihood 
ratio with 
95% C.I.
Post-test 
odds
= 4 1% 4% (3% to 13%) 100% (98% to 
100%)
100% (22 to 
100%)
78% (72% to 
83%)
Undefined Undefined
≥3 6% 26% (15% to 
40%)
100% (98% to 
100%)
100% (81% to 
100%)
82% (76% to 
87%)
Undefined Undefined
≥2 13% 51% (37% to 
65%)
98% (95% to 
100%)
90% (73% to 
98%)
87% (82% to 
91%)
30 (10 to 96) 9
≥1 22% 81% (69% to 
90%)
95% (91% to 
98%)
83% (70% to 
91%)
94% (90% to 
97%)
16 (8 to 31) 5
≥0 100% 100% (93% to 
100%)
0% (0% to 2%) 23% (18% to 
29%)
error 1 0.3
When the specificity is 100%, the likelihood ratio and post test odds are undefined.
Confidence intervals for likelihood ratios are approximate since they were calculated by the delta method which is less reliable when some cell 
sizes are small (Armitage P, Matthews JNS, Berry G. Statistical methods in medical research. Oxford; Blackwell, 1994).BMC Family Practice 2007, 8:49 http://www.biomedcentral.com/1471-2296/8/49
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Multilevel LRs calculated at different HARK scores with
95% confidence intervals and corresponding post-test
odds are shown in table 4.
Discussion
The four HARK questions accurately identify women
experiencing IPV in the past year and may help women
disclose IPV in general practice. The estimated specificity
(95%, 95% C.I. 91% to 98%) of the HARK score of ≥1 was
higher than the sensitivity (81%, 95% C.I. 69% to 90%).
The PPV (post-test probabilities) of HARK, which increase
as the HARK score increases, also provide evidence that
HARK is an effective short tool for identifying IPV.
The most straightforward way of using the HARK is as a
simple test with a cut off of ≥1. Therefore if a clinician asks
these four questions and their patient scores ≥1, this will
identify 81% of women affected by IPV (as judged by the
CAS). This is assuming that the tool performs in the same
way that it did when a researcher administered it. There is
an 83% probability that a woman with this score has
experienced IPV in the past year (positive predictive
value); and she is 16 times more likely to have been
affected by IPV in the last year than some-one with a
HARK score of 0 (likelihood ratio of a positive result).
The multilevel LRs and corresponding post-test odds
make more use of the data from the test as it avoids
dichotomising the HARK score into IPV present or not
present [39]. When a woman is asked the four HARK
questions she does not actually have a positive or negative
score for IPV; instead she may score 0, 1, 2, 3 or 4 and each
score has a different meaning (i.e. different likelihood
ratio and post-test odds for IPV – see table 4). When an
individual answers "no" to all of the HARK questions the
likelihood ratio and post test odds (0.2 and 0.1 respec-
tively) suggest that IPV is probably not present; whereas
answering "yes" to three or four HARK questions produces
a specificity of 100%, meaning that IPV is present.
Answering "yes" to one or two of the HARK questions is
less specific.
The majority of women who are experiencing IPV do not
spontaneously disclose to clinicians. HARK can poten-
tially accurately and quickly identify a high proportion of
these women. This is a pre-requisite for effective interven-
tion allowing the successful management of IPV in gen-
Receiver operator characteristic curve showing sensitivity of  different HARK scores verses 1 - specificity Figure 2
Receiver operator characteristic curve showing sensitivity of 
different HARK scores verses 1 - specificity.
Figure 2: Receiver operator characteristic curve showing sensitivity 
of different HARK scores verses 1 – specificity.
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Table 4: Multilevel likelihood ratios with 95% confidence intervals 
and post-test odds of individual HARK scores.
HARK score 
(number of 
"yeses")
Likelihood ratio 
with 95% C.I.
Post-test odds
3 or 4 Undefined Undefined
2 14.6 (4.3 to 49.4) 4.3
1 9.01 (3.7 to 21.9) 2.67
0 0.2 (0.1 to 0.4) 0.1
Flow diagram to show recruitment of participants to the  study Figure 1
Flow diagram to show recruitment of participants to the 
study.
Figure 1: Flow diagram to show recruitment of participants to the 
study 
Potentially 
eligible women
HARK completed 
232
Abnormal result, 
HARK≥1 = 51
Normal result, 
HARK<1 = 181
Reference standard (CAS) completed 
51
Reference standard (CAS) completed
181
IPV present 
41
IPV present 
9
IPV absent 
172
IPV absent 
10
Too busy to be 
approached 14
Did not come back 
203
Declined participation
in waiting room 186 
Consent declined 
in private room 11
Inclusion criteria 
not met 737BMC Family Practice 2007, 8:49 http://www.biomedcentral.com/1471-2296/8/49
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eral practice. It has been shown that women want to
disclose IPV to health care professionals, particularly pri-
mary care clinicians [18].
The high pre-test probability (prevalence) of IPV (23%) is
consistent with other prevalence studies in primary health
care settings [3].
To increase the external validity of the study, we recruited
a wide range of practices, including small single handed
ones with less than 3,000 patients which are common in
inner city areas in the United Kingdom. However small
practices had fewer patients in the waiting room available
for recruitment than had been anticipated; with the
recruitment of participants taking longer than planned.
Consequently we were only able to recruit 46% of our tar-
get sample size within the timeframe of the study, result-
ing in less precise estimates of test accuracy, reflected in
wider confidence intervals. Nevertheless our study is
larger than some other validation studies of short instru-
ments and our estimates of test characteristics are rela-
tively precise.
Eighty two percent of women who did not fulfil the inclu-
sion criteria were accompanied. The ethics committee that
approved our proposal specified that potential partici-
pants should only be approached if they were unaccom-
panied in order to decrease the likelihood of an abusive
partner discovering that the participant had completed a
questionnaire on domestic violence. We did include
women who were accompanied by children under the age
of five years, as it was felt that a child this young was
unlikely to jeopardise a participant's safety.
Overall women were enthusiastic about participation
once they found out that the study was about domestic
violence: only eleven women declined consent in the pri-
vate room. One hundred and eighty six women declined
participation in the waiting room but these women did
not know that the study was specifically about domestic
violence.
The National Census 2001 figures allowed us to compare
our study population to the local population in the bor-
ough of Newham. The average age of the study population
was 3 years older than the average age in the local popu-
lation (32 years). The percentage of the study population
in a paid job was 12% higher and the percentage that
owned a house or flat was 9% higher than that in the local
population (39% and 44% respectively). The percentage
of the study population that described their ethnic origin
as white British was 6% higher than that in the local pop-
ulation (34%) whilst the percentage that described their
ethnic origin as Indian, Pakistani or Bangladeshi was 11%
lower than that in the local population (29%). This com-
parison shows that despite our attempts, the study popu-
lation were not totally representative of the local
population. We believe that the higher socio-economic
status of our study sample (as reflected by the higher per-
centage in a paid job and owning a house or flat) com-
pared to the local population may reflect a response bias
meaning that perhaps those women with lower socio-eco-
nomic status and at greater risk of IPV were less likely to
have taken part in this study. This may have affected the
calculation of the prevalence, PPV and NPV of HARK.
However there is no reason why this would necessarily
affect the sensitivity/specificity calculations unless the
46% of women who did not take part in the study
answered differently with regards to only one of the
instruments (the HARK or the CAS). This is unlikely.
The strengths of this study are that it tested a short tool
that can be used in routine general practice, against an
abuse measure validated in primary care. Additionally,
HARK's external validity has been increased by being con-
ducted in a range of practices with a study population of
varied ethnicity.
Limitations included the response rate of 54%, decreasing
the external validity of the study. Although we consider
the CAS to be the best research measure for IPV in a health
care setting, we cannot exclude the possibility that not all
women who were found to be positive for IPV with the
HARK but negative with the CAS were false positives.
Other investigators have found that when using two sets
of validated questions each may identify some women as
abused that would have been missed by the other tool
[40].
The HARK questions could be incorporated into elec-
tronic medical records in primary care to prompt clini-
cians to ask about recent intimate partner violence and to
encourage disclosure by patients. Future research should
test the effectiveness of HARK in clinical consultations as
part of system level interventions to improve the response
of primary care to IPV.
Conclusion
Intimate partner violence against women is common and
causes short and long-term ill health. Previously ques-
tions about intimate partner violence to elicit disclosure
have been insufficiently validated for use in general prac-
tice or family medicine populations, particularly outside
the US. The four short HARK questions accurately identify
women experiencing intimate partner violence in the past
year.
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